Latest Breaking News On - Mark litton - Page 4 : comparemela.com

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

Veteran biopharmaceutical executive brings over 30 years of financial, corporate strategy, transactional and business development experienceBOTHELL, Wash., May 22, 2023 Athira Pharma,. | May 22, 2023

United statesMark littonAthira pharmaJulie rathbunMassachusetts institute of technologySecurities exchangeExchange commissionMckinsey coTechnology associate at morgan stanleyCorporate development at amgenAnderson school of managementHead of corporate development at synlogic incAthira pharma incMaster of business administrationNeuraltus pharmaceuticalsAndrew gengos

Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates

Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term. | May 11, 2023

United statesJulie rathbunMark littonAthira pharmaInternational conference on alzheimerAmerican association of neurologySecurities exchangeAthira pharma incDevelopment rd expensesExchange commissionNational institutes of healthClinical development pipeline programsDrug administrationChief executive officerMini mental state examLabel extension

Athira Pharma Announces Promotion of Kevin Church, Ph D , to Chief Scientific Officer

BOTHELL, Wash., Jan. 31, 2023 Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration,. | January 31, 2023

United statesWashington state universityMark littonAthira pharmaJulie rathbunAthira pharma incExchange commissionUniversity of idahoKevin churchSecurities exchangeChief scientificChief executive officerExecutive vice presidentMolecular biosciencesWashington stateSecurities act

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAthira pharmaMark littonContactjulie rathbunathira pharmaAthira pharma incResearch of athira pharmaExchange commissionKevin churchSecurities exchangeNovel positive modulatorPromotes neurotrophicProcognitive effectsExecutive vice presidentChief executive officerScientific publicationsInc athira pharma

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference

16.11.2022 - Fosgonimeton treatment showed results suggestive of neuroprotection and potential disease modification in models of Parkinson’s disease Small molecule positive modulators of HGF/MET improved symptoms of diabetic neuropathy with a persistent . Seite 1

Mark littonAthira pharma incKevin churchSociety for neuroscienceResearch of athira pharmaExecutive vice presidentChief executive officer